Douglas F Covey

US Patent:

6350739, Feb 26, 2002

Filed:

Aug 11, 1999

Appl. No.:

09/372627

Inventors:

James W. Simpkins - Gainesville FL
Douglas F. Covey - Ballwin MO

Assignee:

University of Florida Resarch Foundation, Inc. - Gainesville FL
Washington University - St. Louis MO

International Classification:

A61K 3156

US Classification:

514182, 514179, 514180, 514181

Abstract:

The present invention in various embodiments provides methods of treating stroke and conferring protection on a population of cells associated with ischemia in a subject following an ischemic event, comprising: (a) providing an estrogen compound; and (b) administering the effective amount of the compound over a course that includes at least one dose within a time that is effectively proximate to the ischemic event, so as to confer protection on the population of cells. Novel methods are provided for the delivery of an estrogen compound. Examples of ischemic events treatable according to the invention are cerebrovascular disease or stroke, subarachnoid subhemorrhage, myocardial infarct, surgery and trauma. A method of treating ischemic damage utilizing hormones that are non-sex hormones is also provided. A method of treating stroke with ent-17-estradiol, and a method of synthesis, and compounds produced from the synthesis are provided.

US Patent:

6680331, Jan 20, 2004

Filed:

Jul 16, 2001

Appl. No.:

09/907547

Inventors:

James A. Ferrendelli - Houston TX
Douglas F. Covey - Ballwin MO

Assignee:

Board of Regents, The University of Texas System - Austin TX
Washington University - St. Louis MO

International Classification:

A61K 3140

US Classification:

514327, 514424

Abstract:

This invention relates to lactam and thiolactam derivatives having useful anesthetic and conscious sedation activity. Particularly useful compounds include the diethyl lactams such as 3,3-diethyl-2-pyrrolidinone. Methods for using these compounds and pharmaceutical compositions containing these compounds are provided.

US Patent:

6844456, Jan 18, 2005

Filed:

Nov 5, 2001

Appl. No.:

10/007450

Inventors:

Douglas F. Covey - Ballwin MO, US

Assignee:

Washington University - St. Louis MO

International Classification:

C07J 900
A61K 3156

US Classification:

552545, 514180, 552502

Abstract:

The present invention is directed to modified, hydroxy-bearing aromatic ring structures having cytoprotective activity. More specifically, in a first embodiment the present invention is directed to phenolic compounds, and in particular steriods (e. g. , estrogens), wherein a non-fused polycyclic, hydrophobic substituent is attached to the hydroxy-substituted A-ring thereof. The present invention is further directed to a process for conferring cytoprotection to a population of cells involving the administration of the compound.

US Patent:

7781421, Aug 24, 2010

Filed:

May 28, 2004

Appl. No.:

10/856314

Inventors:

Douglas F. Covey - Ballwin MO, US
Xin Jiang - Baltimore MD, US

Assignee:

Washington University - St. Louis MO

International Classification:

A61K 31/56
A61K 31/58
C07J 53/00
C07J 71/00

US Classification:

514179, 514172, 514173, 540 15, 540 76, 552510

Abstract:

Novel pentacyclic steroids and pentacyclic D-homosteroids comprising: (i) the tetracyclic steroid ring system or tetracyclic D-homosteroid ring system, respectively; (ii) a C(3) substituent selected from the group consisting of (a) a hydroxyl or carboxyl in the α-configuration and (b) a sulfate or other negatively charged moiety; and (iii) a fused fifth ring, the fused fifth ring comprising a hydrogen bond acceptor, and (a) in the case of the pentacyclic steroid the C(13) and C(17) carbons, or (b) in the case of the pentacyclic D-homosteroid the C(13) and C(17a) carbons, having utility as anesthetics and in the treatment of disorders relating to GABA function and activity.

US Patent:

20020132802, Sep 19, 2002

Filed:

Nov 5, 2001

Appl. No.:

10/008567

Inventors:

Douglas Covey - Ballwin MO, US

Assignee:

Washington Univeristy

International Classification:

A61K031/56

US Classification:

514/178000, 514/182000

Abstract:

The present invention is generally directed to novel enantiomeric estrogen derivatives, some of which may have one or more unsaturated bonds in conjugation with the terminal or A-ring of the structure, which have cytoprotective activity. The present invention is further directed to a process for conferring cytoprotection to a population of cells, of a subject in need thereof, involving the administration of an effective dose of the compound.

US Patent:

20030069217, Apr 10, 2003

Filed:

Feb 25, 2002

Appl. No.:

10/082812

Inventors:

James Simpkins - Fort Worth TX, US
Douglas Covey - Ballwin MO, US

International Classification:

A61K031/56

US Classification:

514/182000

Abstract:

The present invention in various embodiments provides methods of treating stroke and conferring protection on a population of cells associated with ischemia in a subject following an ischemic event, comprising: (a) providing an estrogen compound; and (b) administering the effective amount of the compound over a course that includes at least one dose within a time that is effectively proximate to the ischemic event, so as to confer protection on the population of cells. Novel methods are provided for the delivery of an estrogen compound. Examples of ischemic events treatable according to the invention are cerebrovascular disease or stroke, subarachnoid subhemorrhage, myocardial infarct, surgery and trauma. A method of treating ischemic damage utilizing hormones that are non-sex hormones is also provided. A method of treating stroke with ent-17-estradiol, and a method of synthesis, and compounds produced from the synthesis are provided.

US Patent:

20050054624, Mar 10, 2005

Filed:

Oct 22, 2004

Appl. No.:

10/971423

Inventors:

Douglas Covey - Ballwin MO, US

Assignee:

Washington University - St. Louis MO

International Classification:

A61K031/56

US Classification:

514182000

Abstract:

The present invention is directed to a process for conferring cytoprotection on a population of cells which comprises administering to that population of cells a compound comprising a hydroxy-substituted aromatic ring structure and a non-fused polycyclic, hydrophobic substituent attached thereto. In particular, the present invention is directed to such a process wherein the administered compound is phenolic, such as a steriod (e.g., estrogen), and has a non-fused polycyclic, hydrophobic substituent attached to the hydroxy-substituted A-ring thereof.

US Patent:

20100317638, Dec 16, 2010

Filed:

Aug 20, 2010

Appl. No.:

12/860345

Inventors:

Douglas F. Covey - Ballwin MO, US
Xin Jiang - Baltimore MD, US

Assignee:

WASHINGTON UNIVERSITY - St. Louis MO

International Classification:

A61K 31/58
A61P 25/08
A61P 25/24
A61P 25/22
A61P 25/30
A61K 31/575

US Classification:

514173, 514178, 514182, 514172

Abstract:

Novel pentacyclic steroids and pentacyclic D-homosteroids comprising: (i) the tetracyclic steroid ring system or tetracyclic D-homosteroid ring system, respectively; (ii) a C(3) substituent selected from the group consisting of (a) a hydroxyl or carboxyl in the α-configuration and (b) a sulfate or other negatively charged moiety; and (iii) a fused fifth ring, the fused fifth ring comprising a hydrogen bond acceptor, and (a) in the case of the pentacyclic steroid the C(13) and C(17) carbons, or (b) in the case of the pentacyclic D-homosteroid the C(13) and C(17a) carbons, having utility as anesthetics and in the treatment of disorders relating to GABA function and activity.